Abstract
In acute myeloid leukaemia (AML), nucleophosmin-1 (NPM1) mutations create a nuclear export signal (NES) motif and disrupt tryptophans at NPM1 C-terminus, leading to nucleophosmin accumulation in leukaemic cell cytoplasm. We investigated how nucleophosmin NES motifs (two physiological and one created by the mutation) regulate traffic and interaction of mutated NPM1, NPM1wt and p14ARF. Nucleophosmin export into cytoplasm was maximum when the protein contained all three NES motifs, as naturally occurs in NPM1-mutated AML. The two physiological NES motifs mediated NPM1 homo/heterodimerization, influencing subcellular distribution of NPM1wt, mutated NPM1 and p14ARF in a ‘dose-dependent tug of war’ fashion. In transfected cells, excess doses of mutant NPM1 relocated completely NPM1wt (and p14ARF) from the nucleoli to the cytoplasm. This distribution pattern was also observed in a proportion of NPM1-mutated AML patients. In transfected cells, excess of NPM1wt (and p14ARF) relocated NPM1 mutant from the cytoplasm to the nucleoli. Notably, this distribution pattern was not observed in AML patients where the mutant was consistently cytoplasmic restricted. These findings reinforce the concept that NPM1 mutants are naturally selected for most efficient cytoplasmic export, pointing to this event as critical for leukaemogenesis. Moreover, they provide a rationale basis for designing small molecules acting at the interface between mutated NPM1 and other interacting proteins.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Grisendi S, Mecucci C, Falini B, Pandolfi PP . Nucleophosmin and cancer. Nat Rev Cancer 2006; 6: 493–505.
Szebeni A, Olson MO . Nucleolar protein B23 has molecular chaperone activities. Protein Sci 1999; 8: 905–912.
Borer RA, Lehner CF, Eppenberger HM, Nigg EA . Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989; 56: 379–390.
Negi SS, Olson MO . Effects of interphase and mitotic phosphorylation on the mobility and location of nucleolar protein B23. J Cell Sci 2006; 119: 3676–3685.
Tarapore P, Shinmura K, Suzuki H, Tokuyama Y, Kim SH, Mayeda A et al. Thr199 phosphorylation targets nucleophosmin to nuclear speckles and represses pre-mRNA processing. FEBS Lett 2006; 580: 399–409.
Liu X, Liu Z, Jang SW, Ma Z, Shinmura K, Kang S et al. Sumoylation of nucleophosmin/B23 regulates its subcellular localization, mediating cell proliferation and survival. Proc Natl Acad Sci USA 2007; 104: 9679–9684.
Okuwaki M . The structure and functions of NPM1/nucleophsmin/B23, a multifunctional nucleolar acidic protein. J Biochem 2008; 143: 441–448.
Brady SN, Yu Y, Maggi Jr LB, Weber JD . ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway. Mol Cell Biol 2004; 24: 9327–9338.
Sherr CJ . Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 2006; 6: 663–673.
Cordell JL, Pulford KA, Bigerna B, Roncador G, Banham A, Colombo E et al. Detection of normal and chimeric nucleophosmin in human cells. Blood 1999; 93: 632–642.
Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254–266.
Alcalay M, Tiacci E, Bergomas R, Bigerna B, Venturini E, Minardi SP et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood 2005; 106: 899–902.
Falini B, Nicoletti I, Martelli MF, Mecucci C . Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007; 109: 874–885.
Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA 2008; 105: 3945–3950.
Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood 2006; 107: 4514–4523.
Grummitt CG, Townsley FM, Johnson CM, Warren AJ, Bycroft M . Structural consequences of nucleophosmin mutations in acute myeloid leukaemia. J Biol Chem 2008; 34: 23326–23332.
Wang W, Budhu A, Forgues M, Wang XW . Temporal and spatial control of nucleophosmin by the Ran–Crm1 complex in centrosome duplication. Nat Cell Biol 2005; 7: 823–830.
Yu Y, Maggi Jr LB, Brady SN, Apicelli AJ, Dai MS, Lu H et al. Nucleophosmin is essential for ribosomal protein L5 nuclear export. Mol Cell Biol 2006; 26: 3798–3809.
Nakagawa M, Kameoka Y, Suzuki R . Nucleophosmin in acute myelogenous leukemia (letter). N Engl J Med 2005; 352: 1819–1820.
Colombo E, Martinelli P, Zamponi R, Shing DC, Bonetti P, Luzi L et al. Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. Cancer Res 2006; 66: 3044–3050.
den Besten W, Kuo ML, Williams RT, Sherr CJ . Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein. Cell Cycle 2005; 4: 1593–1598.
Quentmeier H, Martelli MP, Dirks WG, Bolli N, Liso A, Macleod RA et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia 2005; 19: 1760–1767.
Nishimura Y, Ohkubo T, Furuichi Y, Umekawa H . Tryptophans 286 and 288 in the C-terminal region of protein B23.1 are important for its nucleolar localization. Biosci Biotechnol Biochem 2002; 66: 2239–2242.
Falini B, Martelli MP, Bolli N, Bonasso R, Ghia E, Pallotta MT et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood 2006; 108: 1999–2005.
Enomoto T, Lindstrom MS, Jin A, Ke H, Zhang Y . Essential role of the B23/NPM core domain in regulating ARF binding and B23 stability. J Biol Chem 2006; 281: 18463–18472.
Bolli N, Nicoletti I, De Marco MF, Bigerna B, Pucciarini A, Mannucci R et al. Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. Cancer Res 2007; 67: 6230–6237.
Chan PK, Chan FY . Nucleophosmin/B23 (NPM) oligomer is a major and stable entity in HeLa cells. Biochim Biophys Acta 1995; 1262: 37–42.
Yung BY, Chan PK . Identification and characterization of a hexameric form of nucleolar phosphoprotein B23. Biochim Biophys Acta 1987; 925: 74–82.
Pasqualucci L, Liso A, Martelli MP, Bolli N, Pacini R, Tabarrini A et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: impact on WHO classification. Blood 2006; 108: 4146–4155.
Mariano AR, Colombo E, Luzi L, Martinelli P, Volorio S, Bernard L et al. Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal. Oncogene 2006; 25: 4376–4380.
Albiero E, Madeo D, Bolli N, Giaretta I, Bona ED, Martelli MF et al. Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation. Leukemia 2007; 21: 1099–1103.
Falini B, Albiero E, Bolli N, De Marco MF, Madeo D, Martelli M et al. Aberrant cytoplasmic expression of C-terminal-truncated NPM leukaemic mutant is dictated by tryptophans loss and a new NES motif. Leukemia 2007; 21: 2052–2054.
Pitiot AS, Santamaria I, Garcia-Suarez O, Centeno I, Astudillo A, Rayon C et al. A new type of NPM1 gene mutation in AML leading to a C-terminal truncated protein. Leukemia 2007; 21: 1564–1566.
Falini B, Martelli MP, Mecucci C, Liso A, Bolli N, Bigerna B et al. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice. Haematologica 2008; 93: 775–779.
Meloni G, Mancini M, Gianfelici V, Martelli M, Foa R, Falini B . Late relapse of AML with mutated NPM1 after 8 years: evidence of NPM1 mutation stability. Haematologica 2008 (in press).
Falini B, Nicoletti I, Bolli N, Martelli MP, Liso A, Gorello P et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica 2007; 92: 519–532.
Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005; 437: 147–153.
Cheng K, Grisendi S, Clohessy JG, Majid S, Bernardi R, Sportoletti P et al. The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence. Oncogene 2007; 26: 7391–7400.
Acknowledgements
This study was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, and by the Fondazione Cassa di Risparmio di Perugia. We are grateful to Dr GA Boyd for editorial assistance. B Falini has applied for a patent on the clinical use of NPM1 mutants. N Bolli is recipient of a Fellowship from FIRC (Federazione Italiana per la Ricerca sul Cancro).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Supplementary information
Rights and permissions
About this article
Cite this article
Bolli, N., De Marco, M., Martelli, M. et al. A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF. Leukemia 23, 501–509 (2009). https://doi.org/10.1038/leu.2008.326
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.326
Keywords
This article is cited by
-
NSC348884 cytotoxicity is not mediated by inhibition of nucleophosmin oligomerization
Scientific Reports (2021)
-
New insights into the biology of acute myeloid leukemia with mutated NPM1
International Journal of Hematology (2019)
-
Biological and clinical consequences of NPM1 mutations in AML
Leukemia (2017)
-
Nucleocapsid Interacts with NPM1 and Protects it from Proteolytic Cleavage, Enhancing Cell Survival, and is Involved in PEDV Growth
Scientific Reports (2017)
-
Structural investigation of nucleophosmin interaction with the tumor suppressor Fbw7γ
Oncogenesis (2017)